Inhibition of tumor formation by snake venom disintegrin

Rong Sen Yang, Chih Hsin Tang, Woei-Jer Chuang, Tsang-Hai Huang, Hui Chin Peng, Tur Fu Huang, Wen Mei Fu

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The metastasis of tumor cells to bone involves migration, invasion and adhesion to bone. Breast and prostate cancer cells have predilection for spreading to bone. Snake venom-derived arginine-glycine-aspartic acid (RGD)-containing disintegrins (e.g. rhodostomin) have been demonstrated to inhibit cell adhesion. Here, we found that rhodostomin inhibited the adhesion of breast and prostate carcinoma cells to both unmineralized and mineralized bone extracellular matrices in a dose-dependent manner, without affecting the viability of tumor cells. In addition, rhodostomin also inhibited the migration and invasion of breast and prostate carcinoma cells. It specifically inhibited the binding of monoclonal antibody (MoAb) 7E3, which recognizes integrin αvβ3, to tumor cells, but not those of other MoAbs against other integrin subunits such as α2, α3, α5 and β1. As breast cancer cells MDA-MB-231 were locally injected into tibia in nude mice, histological examination of the tibia of control group revealed that most of the cancellous bone had been replaced by the breast cancer cells after 28 days' inoculation. In contrast, co-administration of trigramin with cancer cells markedly inhibited tumor growth and bone destruction. Taken together, disintegrins strongly inhibit the adhesion, migration, invasion of tumor cells and also tumor growth of human breast cancer cells in bone as well. Therefore, disintegrins may be developed as alternate therapy for bone metastasis of cancer cells.

Original languageEnglish
Pages (from-to)661-669
Number of pages9
JournalToxicon
Volume45
Issue number5
DOIs
Publication statusPublished - 2005 Jan 1

Fingerprint

Disintegrins
Snake Venoms
Tumors
Cells
Bone
Neoplasms
Breast Neoplasms
Bone and Bones
Adhesion
Tibia
Integrins
Prostate
Neoplasm Metastasis
Bone Neoplasms
Bone Matrix
Bone Development
Cell adhesion
Nude Mice
Aspartic Acid
Cell Adhesion

All Science Journal Classification (ASJC) codes

  • Toxicology

Cite this

Yang, R. S., Tang, C. H., Chuang, W-J., Huang, T-H., Peng, H. C., Huang, T. F., & Fu, W. M. (2005). Inhibition of tumor formation by snake venom disintegrin. Toxicon, 45(5), 661-669. https://doi.org/10.1016/j.toxicon.2005.01.013
Yang, Rong Sen ; Tang, Chih Hsin ; Chuang, Woei-Jer ; Huang, Tsang-Hai ; Peng, Hui Chin ; Huang, Tur Fu ; Fu, Wen Mei. / Inhibition of tumor formation by snake venom disintegrin. In: Toxicon. 2005 ; Vol. 45, No. 5. pp. 661-669.
@article{e19b40787a6c416499d8e6ad5b0b387b,
title = "Inhibition of tumor formation by snake venom disintegrin",
abstract = "The metastasis of tumor cells to bone involves migration, invasion and adhesion to bone. Breast and prostate cancer cells have predilection for spreading to bone. Snake venom-derived arginine-glycine-aspartic acid (RGD)-containing disintegrins (e.g. rhodostomin) have been demonstrated to inhibit cell adhesion. Here, we found that rhodostomin inhibited the adhesion of breast and prostate carcinoma cells to both unmineralized and mineralized bone extracellular matrices in a dose-dependent manner, without affecting the viability of tumor cells. In addition, rhodostomin also inhibited the migration and invasion of breast and prostate carcinoma cells. It specifically inhibited the binding of monoclonal antibody (MoAb) 7E3, which recognizes integrin αvβ3, to tumor cells, but not those of other MoAbs against other integrin subunits such as α2, α3, α5 and β1. As breast cancer cells MDA-MB-231 were locally injected into tibia in nude mice, histological examination of the tibia of control group revealed that most of the cancellous bone had been replaced by the breast cancer cells after 28 days' inoculation. In contrast, co-administration of trigramin with cancer cells markedly inhibited tumor growth and bone destruction. Taken together, disintegrins strongly inhibit the adhesion, migration, invasion of tumor cells and also tumor growth of human breast cancer cells in bone as well. Therefore, disintegrins may be developed as alternate therapy for bone metastasis of cancer cells.",
author = "Yang, {Rong Sen} and Tang, {Chih Hsin} and Woei-Jer Chuang and Tsang-Hai Huang and Peng, {Hui Chin} and Huang, {Tur Fu} and Fu, {Wen Mei}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.toxicon.2005.01.013",
language = "English",
volume = "45",
pages = "661--669",
journal = "Toxicon",
issn = "0041-0101",
publisher = "Elsevier Limited",
number = "5",

}

Yang, RS, Tang, CH, Chuang, W-J, Huang, T-H, Peng, HC, Huang, TF & Fu, WM 2005, 'Inhibition of tumor formation by snake venom disintegrin', Toxicon, vol. 45, no. 5, pp. 661-669. https://doi.org/10.1016/j.toxicon.2005.01.013

Inhibition of tumor formation by snake venom disintegrin. / Yang, Rong Sen; Tang, Chih Hsin; Chuang, Woei-Jer; Huang, Tsang-Hai; Peng, Hui Chin; Huang, Tur Fu; Fu, Wen Mei.

In: Toxicon, Vol. 45, No. 5, 01.01.2005, p. 661-669.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibition of tumor formation by snake venom disintegrin

AU - Yang, Rong Sen

AU - Tang, Chih Hsin

AU - Chuang, Woei-Jer

AU - Huang, Tsang-Hai

AU - Peng, Hui Chin

AU - Huang, Tur Fu

AU - Fu, Wen Mei

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The metastasis of tumor cells to bone involves migration, invasion and adhesion to bone. Breast and prostate cancer cells have predilection for spreading to bone. Snake venom-derived arginine-glycine-aspartic acid (RGD)-containing disintegrins (e.g. rhodostomin) have been demonstrated to inhibit cell adhesion. Here, we found that rhodostomin inhibited the adhesion of breast and prostate carcinoma cells to both unmineralized and mineralized bone extracellular matrices in a dose-dependent manner, without affecting the viability of tumor cells. In addition, rhodostomin also inhibited the migration and invasion of breast and prostate carcinoma cells. It specifically inhibited the binding of monoclonal antibody (MoAb) 7E3, which recognizes integrin αvβ3, to tumor cells, but not those of other MoAbs against other integrin subunits such as α2, α3, α5 and β1. As breast cancer cells MDA-MB-231 were locally injected into tibia in nude mice, histological examination of the tibia of control group revealed that most of the cancellous bone had been replaced by the breast cancer cells after 28 days' inoculation. In contrast, co-administration of trigramin with cancer cells markedly inhibited tumor growth and bone destruction. Taken together, disintegrins strongly inhibit the adhesion, migration, invasion of tumor cells and also tumor growth of human breast cancer cells in bone as well. Therefore, disintegrins may be developed as alternate therapy for bone metastasis of cancer cells.

AB - The metastasis of tumor cells to bone involves migration, invasion and adhesion to bone. Breast and prostate cancer cells have predilection for spreading to bone. Snake venom-derived arginine-glycine-aspartic acid (RGD)-containing disintegrins (e.g. rhodostomin) have been demonstrated to inhibit cell adhesion. Here, we found that rhodostomin inhibited the adhesion of breast and prostate carcinoma cells to both unmineralized and mineralized bone extracellular matrices in a dose-dependent manner, without affecting the viability of tumor cells. In addition, rhodostomin also inhibited the migration and invasion of breast and prostate carcinoma cells. It specifically inhibited the binding of monoclonal antibody (MoAb) 7E3, which recognizes integrin αvβ3, to tumor cells, but not those of other MoAbs against other integrin subunits such as α2, α3, α5 and β1. As breast cancer cells MDA-MB-231 were locally injected into tibia in nude mice, histological examination of the tibia of control group revealed that most of the cancellous bone had been replaced by the breast cancer cells after 28 days' inoculation. In contrast, co-administration of trigramin with cancer cells markedly inhibited tumor growth and bone destruction. Taken together, disintegrins strongly inhibit the adhesion, migration, invasion of tumor cells and also tumor growth of human breast cancer cells in bone as well. Therefore, disintegrins may be developed as alternate therapy for bone metastasis of cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=15044341611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044341611&partnerID=8YFLogxK

U2 - 10.1016/j.toxicon.2005.01.013

DO - 10.1016/j.toxicon.2005.01.013

M3 - Article

VL - 45

SP - 661

EP - 669

JO - Toxicon

JF - Toxicon

SN - 0041-0101

IS - 5

ER -